

10/526,597

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|---|--|
| (51) International Patent Classification ⁶ : A61L | A2 | (11) International Publication Number: WO 99/11298 (43) International Publication Date: 11 March 1999 (11.03.99) |
| <p>(21) International Application Number: PCT/US98/18150</p> <p>(22) International Filing Date: 1 September 1998 (01.09.98)</p> <p>(30) Priority Data: 08/922,068 2 September 1997 (02.09.97) US</p> <p>(71) Applicant: GENSCI REGENERATION LABORATORIES, INC. [US/US]; Suite 100, 8 Pasteur, Irvine, CA 92618 (US).</p> <p>(72) Inventor: CLOKIE, Cameron, M., L.; 118 Sprindrift Drive, Rancho Palos Verdes, CA 90275 (US).</p> <p>(74) Agents: SCHNEIDER, Carol, A. et al.; Lyon & Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US).</p> | <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p> | |
| <p>(54) Title: REVERSE PHASE CONNECTIVE TISSUE REPAIR COMPOSITION</p> <p>(57) Abstract</p> <p>A biocompatible connective tissue repair composition which comprises a therapeutic material and a carrier comprising a means for achieving reverse phase characteristics, and methods for using said composition. The therapeutic material can be demineralized bone powder, and the carrier can be a poloxamer such as poloxamer 407.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

DESCRIPTIONReverse Phase Connective Tissue Repair CompositionField of the Invention

This invention concerns prosthetic materials. More
5 particularly, it concerns a biocompatible material that
exhibits reverse phase behavior.

Background Art


Osteogenic bone repair materials are known in the
art. These materials contain an osteogenic material, such
10 as demineralized bone powder in a carrier, such as
glycerol. See, e.g., U.S. Patent 5,290,558, issued 1 March
1994 to O'Leary et al., and U.S. Patent 5,284,655, issued
8 February 1994 to Bogdansky et al.

The carrier of the bone material in the art is a
15 liquid, having a viscosity generally somewhere between
runny to paste-like. "Runny" bone repair compositions have
the advantage of being relatively easy to apply to and
fill a bone defect, however, they are disadvantageous in
that the material also tends to readily flow from the
20 defect site. Conversely, bone repair compositions with a
"paste-like" consistency are harder to apply to a defect,
yet tend to remain positioned at the defect once applied.
Additionally, when any of the bone repair compositions in
the art are placed in vivo and become warmed, they become
25 even less viscous; the decrease in viscosity is due to the
addition of thermal energy to the composition.

Accordingly, there is a need for a bone repair
composition that is easy to apply to a defect site, and
which remains positioned at the site once placed at the
30 site.

Disclosure Of The Invention

Disclosed is a biocompatible composition to facilitate repair of connective tissues. The composition can comprise demineralized bone powder, and, a carrier comprising a means for achieving reverse phase thermodynamic characteristics when mixed with the bone powder. The composition can be substantially liquid at 0°C., and substantially more viscous at 35°C., such that the composition has a consistency like that of paste floor wax or like solid shoe wax. The means for achieving reverse phase characteristics can comprise a block copolymer, such as a poly(oxyalkylene) block copolymer, which can be a poly(oxyethylene)-poly(oxypropylene)-poly(oxyethylene) triblock copolymer. The triblock copolymer can be a compound of the formula:



The means for achieving reverse phase characteristics comprises a poloxamer, such as poloxamer 407. The block copolymer can be a solid dissolved in a biocompatible solvent such as sterile water.

Preferably, the composition comprises a carrier of 25 weight percent of a block copolymer dissolved in 75 weight percent of a biocompatible solvent. To vary the consistency of the composition, the weight percentage of demineralized bone powder or other solid can be varied relative to the weight percentage of the carrier in the composition. For example, a paste-like form of the composition comprises 50 weight percent of bone powder and 50 weight percent of a carrier solution. A gel-like embodiment of the composition comprises 70 weight percent of bone powder and 30 weight percent of a carrier solution.

The bone powder of the composition can comprise particles with a median length to a median thickness ratio of about 1.742:1, a mean length of 0.25-1 mm (250-1,000 microns), and a mean thickness of about 0.5 mm (500 5 microns).

Also disclosed is a method to facilitate the development of bone tissue, said method comprising: providing a biocompatible connective tissue repair composition comprising demineralized bone powder, and, a carrier 10 comprising a means for achieving reverse phase thermodynamic characteristics when mixed with the bone powder; and, placing the composition in a bony defect of a mammal. A prosthetic object can also be placed in the bony defect. The method can also comprise coating a portion of the 15 prosthetic object with the biocompatible composition, and in this embodiment the step of placing the composition and the step of placing a prosthetic object can be contemporaneous.

Modes For Carrying Out Invention

20 Definitions

By "reverse phase" or "reverse thermal behavior" is intended a material that exhibits a physical property of becoming more viscous or solidified upon addition of thermal energy. It is believed that the solidification 25 occurs by a mechanism other than that due to evaporation and corresponding loss of liquid.

As used herein, "ambient temperature" is 25°C., plus or minus 5°C.

As used herein, "body temperature" is 37°C., plus or 30 minus 5°C.

As used herein, a "bony defect" or "bone defect site" is bony environment of a mammal which comprises some

viable bone tissue. The defect can be congenital, caused by trauma, or caused by disease.

"Osteoinductive" materials cause undifferentiated cells to differentiate into a committed bone cell lines.

5 "Osteoinductive" materials provide support for cells of a bone cell lineage, e.g., permitting cells of a bone cell lineage to grow along or through a matrix or lattice.

Preferred Modes

10 In a preferred embodiment, the composition of the present invention is a flowable liquid when applied to a bony defect, whereupon the composition becomes increasingly solidified or viscous as it warms to ambient and is further solidified as it warms to body temperature. Upon being warmed to body temperature, a preferred composition
15 of the invention is a solid or highly viscous fluid. The reverse phase compositions in accordance with the invention are significantly different in principle from bone repair materials in the art, and do not function in the same way.

20 The composition comprises a therapeutic material for treating one or more connective tissues; and, a carrier. The therapeutic material can be a material to facilitate repair of connective tissues, i.e., a "connective tissue repair material." The carrier achieves reverse phase
25 characteristics when mixed with the therapeutic material.

The therapeutic material can be a material that is osteoinductive, osteoconductive, or a material that is osteoinductive and osteoconductive. The therapeutic material can be xenogeneic, allogeneic, or autogenic. The
30 therapeutic material can be alloplastic. As appreciated by one of ordinary skill in the art, the therapeutic material can comprise combinations of various therapeutic materials.

Examples of osteoinductive material include but are not limited to bone powder (mineralized or demineralized), tissue growth factor beta (TGF- β) types 1 through 13, bone morphogenetic protein (BMP) types 1 through 15, or combinations thereof.

Examples of therapeutic materials that are osteoconductive include but are not limited to xenogeneic bone (mineralized or demineralized); the xenogeneic bone can also be subjected to deproteination. Presently preferred xenogeneic source are porcine and bovine.

Therapeutic materials that are osteoinductive and osteoconductive include particulate human allograft, e.g., of demineralized bone.


Examples of alloplastic materials comprise gypsum, coralline hydroxyapatite, synthetic hydroxyapatite, calcium carbonate, calcium phosphate, calcium sulfate, biodegradable polymeric materials, or combinations thereof.

A presently preferred composition comprises demineralized osteogenic bone powder in a carrier; the composition can be applied to a bone defect site to induce new bone growth. This composition of the present invention comprises demineralized bone particles or granules (referred to herein as "demineralized bone powder") in an inert biocompatible carrier.

In a preferred embodiment, the particles/granules have a median length to median thickness ratio about 1.742:1, a mean length of 0.25-1 mm (250-1,000 microns) and a mean thickness of about 0.5 mm (500 microns).

The presently preferred biocompatible carrier of the composition of the invention is a material that confers reverse phase thermodynamic properties on the composition. The use of PLURONIC® F127 as a component of an osteointegration promoting composition is set forth in U.S. Patent 5,503,558, issued 2 April 1996 to the inventor

herein, Cameron C.L. Clokie; and in PCT International Publication No. WO 95/13099. In a presently preferred embodiment, the carrier comprises a polymer marketed by BASF (Parsipanny, New Jersey) as PLURONIC® F127. PLURONIC® F127 is a poly(oxyalkylene) block copolymer; more specifically, a poly(oxyethylene)-poly(oxypropylene)-poly(oxyethylene) poly(oxyethylene) triblock copolymer; it is a member of a class of compounds called poloxamers. (Schmolka, "A Review of Block Polymer Surfactants" J. Am. Oil Chemists Soc. 54:110-116 (1977)). Several members of the poloxamer family exhibit reverse phase thermodynamic characteristics. PLURONIC® F127 is also known by the name "poloxamer 407." (Schmolka, "A Comparison of Block Polymer Surfactant Gels" J. Am. Oil Chemist Soc. 68:206-209 (1991)). PLURONIC® F127 has an average molecular weight of approximately 12,500. (Schmolka, "A Comparison of Block Polymer Surfactant Gels" J. Am. Oil Chemist Soc. 68:206-209 (1991)) The structure of the PLURONIC® F127 polymer is depicted as follows:



In preferred embodiments of a composition of the present invention, the carrier is a liquid diluted in a solvent or is a solid dissolved in a solvent. In one embodiment, PLURONIC® F127 is dissolved in a solvent such as sterile water. The PLURONIC® F127 carrier is vastly different in size, molecular weight; and chemical structure than carriers in the art. The carrier is also substantially different in terms of its functional properties than any carrier of a bone repair material in the art.

The proposed composition has a unique physical property, being flowable at refrigerated temperatures and

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/18150

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| WO 9718829 A | 29-05-1997 | JP 9143093 A | 03-06-1997 |
| | | AU 7586996 A | 11-06-1997 |
| | | CA 2235400 A | 29-05-1997 |
| | | EP 0884052 A | 16-12-1998 |
| | | NO 982236 A | 26-06-1998 |
| WO 9513099 A | 18-05-1995 | US 5503558 A | 02-04-1996 |
| | | AU 688406 B | 12-03-1998 |
| | | AU 8102894 A | 29-05-1995 |
| | | AU 8102994 A | 29-05-1995 |
| | | CA 2151613 A | 18-05-1995 |
| | | CA 2176023 A | 18-05-1995 |
| | | WO 9513028 A | 18-05-1995 |
| | | DE 69412120 D | 03-09-1998 |
| | | EP 0679098 A | 02-11-1995 |
| | | EP 0726741 A | 21-08-1996 |
| | | JP 8505559 T | 18-06-1996 |
| | | US 5702695 A | 30-12-1997 |
| EP 0551626 A | 21-07-1993 | CA 2085690 A | 20-06-1993 |
| | | JP 5262670 A | 12-10-1993 |
| US 5284655 A | 08-02-1994 | US 5073373 A | 17-12-1991 |
| | | US 5290558 A | 01-03-1994 |
| | | DE 69016331 D | 09-03-1995 |
| | | DE 69016331 T | 21-09-1995 |
| | | EP 0419275 A | 27-03-1991 |
| | | JP 1851817 C | 21-06-1994 |
| | | JP 3210270 A | 13-09-1991 |
| | | US 5439684 A | 08-08-1994 |
| | | US 5484601 A | 16-01-1996 |
| | | US 5298254 A | 29-03-1994 |
| US 5520923 A | 28-05-1996 | AU 3104295 A | 09-04-1996 |
| | | WO 9609078 A | 28-03-1996 |

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/18150

Box I Observations where certain claims were found unsearchable (Continuation of item 1. of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 26-28
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 26-28 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims: it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Inter. Application No

PCT/US 98/18150

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|---|-----------------------|
| Y | US 5 284 655 A (BOGDANSKY SIMON ET AL) 8 February 1994 cited in the application see claims | 1-28 |
| A | US 5 520 923 A (TJIA JANE S ET AL) 28 May 1996 | |

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/18150

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61L27/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61L A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X | WO 97 18829 A (HOECHST JAPAN ;SHIMURA TAKESADA (JP); TORIYAMA SATSUKI (JP)) 29 May 1997 see abstract | 1-28 |
| E | -& EP 0 884 052 A16 December 1998 --- | |
| X | WO 95 13099 A (UNIV MCGILL ;CLOKIE CAMERON MALCOLM LANG (CA)) 18 May 1995 cited in the application see page 12, line 33 - line 35 see page 13 - page 14; claims --- | 1-28 |
| Y | EP 0 551 626 A (LEK TOVARNA FARMACEVTSKIH) 21 July 1993 see the whole document --- | 1-28 |
| | -/-- | |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone.

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

23 April 1999

Date of mailing of the international search report

03/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

ESPINOSA, M

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | NZ | New Zealand | | |
| CM | Cameroon | | | PL | Poland | | |
| CN | China | KR | Republic of Korea | PT | Portugal | | |
| CU | Cuba | KZ | Kazakhstan | RO | Romania | | |
| CZ | Czech Republic | LC | Saint Lucia | RU | Russian Federation | | |
| DE | Germany | LI | Liechtenstein | SD | Sudan | | |
| DK | Denmark | LK | Sri Lanka | SE | Sweden | | |
| EE | Estonia | LR | Liberia | SG | Singapore | | |

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|-----------|--|
| (51) International Patent Classification ⁶ : A61L 27/00 | A3 | (11) International Publication Number: WO 99/11298 (43) International Publication Date: 11 March 1999 (11.03.99) |
| (21) International Application Number: PCT/US98/18150 (22) International Filing Date: 1 September 1998 (01.09.98) (30) Priority Data: 08/922,068 2 September 1997 (02.09.97) US (71) Applicant: GENSCI REGENERATION LABORATORIES, INC. [US/US]; Suite 100, 8 Pasteur, Irvine, CA 92618 (US). (72) Inventor: CLOKIE, Cameron, M., L.; 118 Sprindrift Drive, Rancho Palos Verdes, CA 90275 (US). (74) Agents: SCHNEIDER, Carol, A. et al.; Lyon & Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071-2066 (US). | | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 17 June 1999 (17.06.99) |
| (54) Title: REVERSE PHASE CONNECTIVE TISSUE REPAIR COMPOSITION (57) Abstract <p>A biocompatible connective tissue repair composition which comprises a therapeutic material and a carrier comprising a means for achieving reverse phase characteristics, and methods for using said composition. The therapeutic material can be demineralized bone powder, and the carrier can be a poloxamer such as poloxamer 407.</p> | | |

23. The composition of claim 21, wherein 30 weight percent of the therapeutic material is dispersed in 70 weight percent of the carrier.

24. The composition of claim 21, wherein 50 weight percent of the therapeutic material is dispersed in 50 weight percent of the carrier.

25. The composition of claim 10 wherein the therapeutic material comprises bone powder, and the bone powder comprises particles with a median length to a median thickness ratio of about 1.742:1, a mean length of 0.25-1 mm (250-1,000 microns), and a mean thickness of about 0.5 mm (500 microns).

26. A method to facilitate the development of bone tissue, said method comprising:
15 providing the composition of claim 10; and, placing the composition in a bony defect of a mammal.

27. The method of claim 26, further comprising a step of placing a prosthetic object in the bony defect.

28. The method of claim 27, wherein the composition coats a portion of the prosthetic object, and the step of placing the composition and the step of placing a prosthetic object are contemporaneous.

17

15. The composition of claim 10, wherein the means for achieving reverse phase characteristics comprises a poloxamer.

16. The composition of claim 15, wherein the means
5 for achieving reverse phase characteristics comprises poloxamer 407.

17. The composition of claim 10, wherein the means for achieving reverse phase characteristics comprises a block copolymer.

10 18. The composition of claim 17, wherein the means for achieving reverse phase characteristics comprises a poly(oxyalkylene) block copolymer.

19. The composition of claim 18, wherein the means for achieving reverse phase characteristics comprises a
15 poly(oxyethylene)-poly(oxypropylene)-poly(oxyethylene) triblock copolymer.

20. The composition of claim 19, wherein the triblock copolymer comprises a formula:



20



21. The composition of claim 17, wherein the block copolymer is a solid and is dissolved in a biocompatible solvent.

25 22. The composition of claim 21, wherein the biocompatible solvent is sterile water.

8. The composition of claim 1, wherein 50 weight percent of the bone powder is dispersed in 50 weight percent of the carrier.

9. The composition of claim 1 wherein the bone powder comprises particles with a median length to a median thickness ratio of about 1.742:1, a mean length of 0.25-1 mm (250-1,000 microns), and a mean thickness of about 0.5 mm (500 microns).

10. A biocompatible connective tissue repair composition comprising:
a therapeutic material, and,
a carrier comprising a means for achieving reverse phase characteristics.

11. The composition of claim 10, wherein the therapeutic material is osteoinductive, osteoconductive, or osteoinductive and osteoconductive.

12. The composition of claim 10, wherein the therapeutic material is alloplastic, xenogeneic, allogeneic, or autogenic.

13. The composition of claim 10, whereby the means for achieving reverse phase characteristics causes the composition to be substantially liquid at 0°C., and substantially solid at 35°C.

14. The composition of claim 10 which has a first viscosity at 0°C., and a second viscosity at 35°C., wherein the second viscosity is at least twice as great as the first viscosity.

Claims

1. A biocompatible connective tissue repair composition comprising:

demineralized bone powder, and,

5 a carrier comprising a liquid poloxamer solution or a solid poloxamer dissolved in a solvent, whereby said carrier achieves reverse phase characteristics when mixed with the demineralized bone powder.

2. The composition of claim 1, whereby the carrier
10 causes the composition to be substantially liquid at 0°C., and substantially solid at 35°C.

3. The composition of claim 1 which has a first viscosity at 0°C., and a second viscosity at 35°C., wherein the second viscosity is at least twice as great as
15 the first viscosity.

4. The composition of claim 1, wherein carrier comprises a solid poloxamer dissolved in a solvent, and the poloxamer is poloxamer 407.

5. The composition of claim 4 wherein the solvent
20 is sterile water.

6. The composition of claim 5 wherein 25 weight percent of the poloxamer 407 is dissolved in 75 weight percent of the sterile water.

7. The composition of claim 1, wherein 30 weight
25 percent of the bone powder is dispersed in 70 weight percent of the carrier.

composition putty is removed with the spatula or other hand-held instrument.

Appropriate placement of the composition and/or fixation are critical factors in the avoidance of
5 potentially adverse effects on product service life.

Accordingly, the DynaGraft™ Putty is bacteriologically sterile during the stated shelf life in an unopened and undamaged package. The product must be used before the expiration date. Unused product should be properly
10 discarded.

Closing

It must be noted that as used herein and in the appended claims, the singular forms "a," "and," and "the" include plural referents unless the context clearly
15 dictates otherwise. Thus, for example, reference to "a formulation" includes mixtures of different formulations and reference to "the method of treatment" includes reference to equivalent steps and methods known to those skilled in the art, and so forth.

20 Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar to or equivalent to those described herein can be
25 used in the practice or testing of the invention, the preferred methods and materials are now described. All publications mentioned herein are fully incorporated herein by reference.

grafting procedures. DynaGraft™ Putty may be used alone as a bone graft in cases in which the graft is not intended to provide weight bearing support or dimensional integrity to the graft site. If the graft is intended to be weight bearing, the composition should be used with appropriate fixation. DynaGraft™ Putty can, therefore, be used as a complement to musculoskeletal implants such as joint replacement prostheses, intraoral implants, and internal and external fixation devices for procedures in which demineralized freeze-dried bone allograft would be used.

The composition is sterilized by a targeted 2.5 megarads of electron beam irradiation as terminal sterilization. When implanting the composition, sterile technique should be maintained to minimize the risk of post-operative complications. Use of the composition is contraindicated when there is active or latent infection at or near the surgical site.

The composition should be stored long-term in a clean, dry place at room temperature. It should be kept out of direct sunlight and should not be frozen. DynaGraft™ Putty does not require rehydration prior to use.

The packaging of all DynaGraft™ implant compositions has been specially designed to provide ease of use within the surgical field. For example, the composition can be packaged within jars that are kept sterile within one or more foil containers. DynaGraft™ Putty Gel is supplied in 2.5 cc, 5 cc, and 10 cc jars.

To use the composition packaged in jars within foil containers, the packaging is opened by peeling open the outer foil and, using sterile technique, transferring the entire inner package to the sterile field. The inner package is then opened and the jar and a spatula are removed. The jar lid is opened in a sterile manner and

weight percent of PLURONIC® F127 powder dissolved in 75 weight percent sterile water.

A composition of the invention is available as DynaGraft™ Putty (GenSci Regeneration Laboratories, Inc., Irvine, CA); this product is a composition comprising demineralized allograft bone from a single donor mixed with an inert preservative and a biocompatible carrier. The composition has a "putty-like" consistency and is provided in a sterile, single patient use package.

10 The tissues used in the bone repair composition are recovered by United States tissue banks, from carefully screened donors, according to standards established by the American Association of Tissue Banks. All such tissues meet stringent specifications during donor screening and
15 laboratory testing in order to reduce the risk of transmitting any infectious disease.

For example, each donor is tested and found to be negative for (at a minimum): hepatitis B surface antigen, human immunodeficiency virus 1 and 2 antibodies, HTLV-1
20 antibody, hepatitis C virus antibody, and syphilis. The tests were performed by a CLIA approved laboratory utilizing FDA-licensed test kits. The medical and social history of the donor revealed no risk factors for, or clinical evidence of, HIV or hepatitis infection.

25 This biocompatible composition in accordance with the invention was produced under environmentally controlled conditions using stringent cleaning, preservation, and sterilization procedures. All steps are rigorously quality controlled in accordance with accepted methodologies in
30 the art.

DynaGraft™ Putty is indicated for use in surgical procedures in which osteogenesis, calcification or bony fusion is needed to achieve or enhance the quality of the final result. Accordingly, DynaGraft™ Putty can be used in
35 a variety of orthopedic, reconstructive, and dental bone

indicated when there is active or latent infection at or near the surgical site.

The composition should be stored long-term in a clean, dry place at room temperature. It should be kept
5 out of direct sunlight and should not be frozen. DynaGraft™ Gel does not require rehydration prior to use.

The packaging of all DynaGraft™ implant compositions has been specially designed to provide ease of use within the surgical field. For example, the composition can be
10 packaged within syringes that are kept sterile within one or more foil containers. DynaGraft™ Gel is supplied in 1.0 cc, 5 cc, and 10 cc syringes.

To use the composition packaged in syringes within foil containers, the packaging is opened by peeling open
15 the outer foil and, using sterile technique, transferring the entire inner package to the sterile field. The inner package is then opened and the syringe removed. Immediately before use, a protective cap which covers the tip of the syringe is removed. The composition is then
20 extruded by pushing on the syringe plunger to deliver the desired volume. Appropriate placement and/or fixation are critical factors in the avoidance of potentially adverse effects on product service life.

Accordingly, the DynaGraft™ Gel is bacteriologically
25 sterile during the stated shelf life in an unopened and undamaged package. The product must be used before the expiration date. Unused product should be properly discarded.

Example 2

30 To obtain a composition having a paste-like consistency, the composition comprised 50 weight percent of a solution of PLURONIC® F127 and 50 weight percent of bone powder. In this example, the carrier comprised 25

For example, each donor is tested and found to be negative for (at a minimum): hepatitis B surface antigen, human immunodeficiency virus 1 and 2 antibodies, HTLV-1 antibody, hepatitis C virus antibody, and syphilis. The 5 tests were performed by a CLIA approved laboratory utilizing FDA-licensed test kits. The medical and social history of the donor revealed no risk factors for, or clinical evidence of, HIV or hepatitis infection.

This biocompatible composition in accordance with the 10 invention was produced under environmentally controlled conditions using stringent cleaning, preservation, and sterilization procedures. All steps are rigorously quality controlled in accordance with accepted methodologies in the art.

15 DynaGraft™ Gel is indicated for use in surgical procedures in which osteogenesis, calcification or bony fusion is needed to achieve or enhance the quality of the final result.

Accordingly, DynaGraft™ Gel can be used in a variety 20 of orthopedic, reconstructive, and dental bone grafting procedures. DynaGraft™ Gel may be used alone as a bone graft in cases in which the graft is not intended to provide weight bearing support or dimensional integrity to the graft site. If the graft is intended to be weight 25 bearing, the composition should be used with appropriate fixation. DynaGraft™ Gel can, therefore, be used as a complement to musculoskeletal implants such as joint replacement prostheses, intraoral implants, and internal and external fixation devices for procedures in which 30 demineralized freeze-dried bone allograft would be used.

The composition is sterilized by a targeted 2.5 megarads of electron beam irradiation as terminal sterilization. When implanting the composition, sterile technique should be maintained to minimize the risk of post- 35 operative complications. Use of the composition is contra-

In a composition of the invention, the weight percentages of the therapeutic material and the carrier can each be varied. For example, the weight percent of the therapeutic material can vary between about 20 to 80 weight percent of the composition, and the weight percent of the carrier can vary between about 20 to 80 weight percent of the composition. Furthermore one or more additional components can be present in a composition of the invention, such as antibiotics, analgesic, anti-inflammatory agents, or agents to promote development of connective or circulatory system tissues.

Examples

Example 1

To obtain a composition having a gel-like consistency, the composition comprised 70 weight percent of a solution of PLURONIC® F127 and 30 weight percent of bone powder. In this example, the carrier comprised 25 weight percent of PLURONIC® F127 powder dissolved in 75 weight percent sterile water.

A composition of the invention is available as DynaGraft™ Gel (GenSci Regeneration Laboratories, Inc., Irvine, CA); this product is a composition comprising demineralized allograft bone from a single donor mixed with an inert preservative and a biocompatible carrier. The composition has a "gel" consistency and is provided in a sterile, single patient use package.

The tissues used in the bone repair composition are recovered by United States tissue banks, from carefully screened donors, according to standards established by the American Association of Tissue Banks. All such tissues meet stringent specifications during donor screening and laboratory testing in order to reduce the risk of transmitting any infectious disease.

temperature. However, the preferred carrier in a composition of the present invention becomes less flowable as energy is added to it either by heating or by shaking.

The unique reverse phase thermodynamic properties of the composition of the present invention allow the product to function in a substantially different, and preferred manner relative to other flowable bone repair products. When applied to a bone defect site, the reverse phase property of the preferred carrier provides support characteristics for the composition which are substantially different than the characteristics of standard carriers. Enhanced support is provided by the composition of the invention. The preferred PLURONIC® F127 carrier of the composition of the present invention helps to provide support characteristics which are unlike those of any standard carrier. This is because the composition is flowable at ambient temperature and can thus readily be applied to a bony defect site, but it becomes increasingly viscous and solidified once it is warmed at the site. The solidification of the composition of the present invention achieves several; beneficial effects. When solidified, the composition does not flow away from the defect site, and the solidified product immediately augments and facilitates structural support at the defect. Also, since the osteogenic composition of the invention is initially liquid, it readily fills a defect, then becomes solidified and achieves enhanced osteogenesis. Moreover, with preferred compositions of the invention, comprising a sterile aqueous solution of PLURONIC® F127 as carrier and demineralized bone powder, the carrier will resorb or dissolve after about three days, leaving the osteogenic bone powder at the bone defect site. It is believed to be advantageous that the carrier dissolves as this then allows for enhanced ingrowth of connective or vascular tissues.

increasingly solidified at elevated temperatures, such as ambient and body temperatures. This property is referred to in the art as "reverse phase" or "reverse thermal behavior". Due to the reverse phase property of the proposed composition, the composition is generally manufactured at refrigerated temperatures, such as 5°C. Manufacturing is done at refrigerated temperatures to enhance mixing of the components of the composition, since the proposed composition comprising an aqueous solution of PLURONIC® F127 begins to become more viscous at ambient temperature, and is increasingly viscous and solidified at body temperature. Generally, a composition of the invention will be twice as viscous at 35°C. as it is at 0°C.

For example, the preferred PLURONIC® F127 carrier in the composition of the present invention (when dissolved in an appropriate amount of sterile water), has the unique property of being a liquid at ambient temperature and increasingly solidified, then solid at elevated temperature, absent the effects of evaporation and concomitant loss of water. This property is called "reverse phase" or "reverse thermal behavior" because it is the exact opposite of the thermodynamic properties exhibited by standard carriers.

It is believed that the reverse phase property is due, at least in part, to the fact that PLURONIC® F127 is composed of discrete blocks of both hydrophilic (i.e., oxyethylene) and hydrophobic (i.e., oxypropylene) subunits. (See e.g., Schmolka, "A Comparison of Block Polymer Surfactant Gels" J. Am. Oil Chemist Soc. 68:206-209 (1991)).

In contrast, standard carriers, as well as all liquids, manifest the typical physical property of becoming increasingly flowable upon addition of thermal energy, such as occurs when the liquid is heated to body